JAK2 inhibition with ruxolitinib could also impair CML cell immune evasion by preventing the BCR::ABL1-independent MHC-II downregulation that has been observed in CML HSPCs [95]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.